the present disclosure relates to compositions , kits , uses , systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes . preferably , the subject has had type - two diabetes for a period of less than 6 years or is a current smoker , optionally that does not have type - two diabetes .